JMP keeps NxStage at market outperform

NxStage Medical, Inc. was reiterated at market outperform by JMP Securities analyst Robert C. Faulkner on news that the Food and Drug Administration approved the company's PureFlow SL dialysate-processing module. The device will allow patients to use a concentrate to mix dialysate themselves instead of handling bagged fluids. JMP estimates the PureFlow SL could increase gross margins by 700 bps if 100% of the user base switched from fluids supplied by the company's Mexican supplier. Shares of the Lawrence, Mass., medical device company were up 39 cents, or 3.09%, at $13.03 on volume of 142,750 shares versus the three-month running average of 38,201 shares. (Nasdaq: NXTM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.